PANEL FINDS SHORTCOMINGS IN BONE STUDY
Timothy R. Kuklo
The report on the investigation  which was conducted by a panel at Washington University into a study by Dr. Timothy R. Kuklo  was completed on Wednesday.
 Kuklo resigned his post at Washington University this summer amid a controversy over the study  which involved a Medtronic bone growth product called Infuse.
 Kuklo conducted the research in question while a surgeon at Walter Reed Army Medical Center in Washington. He became a highly paid consultant to Medtronic when he joined Washington University in St. Louis in mid-2006.
 In a report last year  Army officials accused him of inflating the number of combat soldiers whose leg injuries had been successfully treated with the product. Officials also found that he had forged the names of four Army doctors before submitting the study to a medical journal for publication.
 After a lengthy review  the Washington University panel concluded that it had been possible for Kuklo to support the number of leg injuries he reported if such injuries were defined broadly. The panel also raised the possibility that some of the data discrepancies had reflected problems in Walter Reed's patient record-keeping system.
Kuklo to support the number of leg injuries he reported if such injuries were defined broadly. The panel also raised the possibility that some of the data discrepancies had reflected problems in Walter Reed's patient record-keeping system.
 Seizing on that finding  Kuklo's lawyer sent a letter on Thursday to Sen. Charles E. Grassley  describing it as exonerating his client. Grassley  a R-Iowa  began an investigation of Kuklo's study after it was the subject of a Page 1 article in The New York Times in May.
 In his presentations to the panel  Kuklo maintained that he had included the other doctors' names as a courtesy and had not intended to mislead any one. But the committee disagreed  finding that Kuklo's decision to use four different handwriting styles to sign for the physicians suggested "intentional deception."
 The panel also found that Kuklo had committed research misconduct in representations he made about another study. As a result of the controversy surrounding his Infuse study  Medtronic suspended his consulting agreement.
 In recommending sanctions  the panel pointed out that Kuklo had already left the institution voluntarily. In its statement  Washington University said that his resignation was not being reconsidered.
The report on the investigation  which was conducted by a panel at Washington University into [TGT]was completed on Wednesday.
 [TGT] resigned [TGT] post at Washington University this summer amid a controversy over the study  which involved a Medtronic bone growth product called Infuse.
 [TGT] conducted the research in question while a surgeon at Walter Reed Army Medical Center in Washington. [TGT] became a highly paid consultant to Medtronic when [TGT] joined Washington University in St. Louis in mid-2006.
 In a report last year  Army officials accused [TGT] of inflating the number of combat soldiers whose leg injuries had been successfully treated with the product. Officials also found that [TGT] had forged the names of four Army doctors before submitting [TGT] to a medical journal for publication.
 After a lengthy review  the Washington University panel concluded that it had been possible for [TGT] to support the number of leg injuries [TGT] reported if such injuries were defined broadly. The panel also raised the possibility that some of the data discrepancies had reflected problems in Walter Reed's patient record-keeping system.
[TGT] to support the number of leg injuries [TGT] reported if such injuries were defined broadly. The panel also raised the possibility that some of the data discrepancies had reflected problems in Walter Reed's patient record-keeping system.
 Seizing on that finding  [TGT]'s lawyer sent a letter on Thursday to Sen. Charles E. Grassley  describing it as exonerating his client. Grassley  a R-Iowa  began an investigation of [TGT]'s study after it was the subject of a Page 1 article in The New York Times in May.
 In his presentations to the panel  [TGT] maintained that he had included the other doctors' names as a courtesy and had not intended to mislead any one. But the committee disagreed  finding that [TGT]'s decision to use four different handwriting styles to sign for the physicians suggested "intentional deception."
 The panel also found that [TGT] had committed research misconduct in representations he made about another study. As a result of the controversy surrounding his Infuse study  Medtronic suspended his consulting agreement.
 In recommending sanctions  the panel pointed out that [TGT] had already left the institution voluntarily. In its statement  Washington University said that his resignation was not being reconsidered.